Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
25 participants
INTERVENTIONAL
2017-04-03
2017-07-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Therefore, we intend to perform 31P-MRS before and after oral intake of the nutrition product.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
nutrition product
Peptamen® 1.5 Vanilla, orally administration
Peptamen® 1.5 vanilla
Administration orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Peptamen® 1.5 vanilla
Administration orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy, based on the medical screening visit
* Normal BMI for age (18.5-25.0 kg/m2)
* Able to understand and to sign a written informed consent prior to trial entry
* Informed consent signed
Exclusion Criteria
* Family history of type 2 diabetes (parents)
* Any other metabolic disease possibly impacting the postprandial glucose and insulin response (on anamnesis, to the opinion of the medical expert)
* Malabsorptive disorders including but not limited to pancreatitis, Crohn's disease, etc
* Any history of neurological / psychological disease (meningitis, epilepsy), to the opinion of the investigator
* Claustrophobia
* Hearing disorders
* Any medication impacting dietary fat absorption and metabolism like statins, bile acid sequestrants, lipid lowering medications, or fibrates , to the opinion of the medical expert
* Pregnancy (on anamnesis) and/or lactation
* Having any metallic, electronic, magnetic, or mechanical implants, devices, or objects, for safety reason linked to magnetic field exposure (MRS):
* Aneurysm clip(s)
* Cardiac pacemaker
* Implanted cardioverter defibrillator (ICD)
* Electronic implant or device
* Magnetically-activated implant or device
* Neurostimulation system
* Spinal cord stimulator
* Cochlear implant or implanted hearing aid
* Insulin or infusion pump
* Implanted drug infusion device
* Any type of prosthesis or implant
* Artificial or prosthetic limb
* Any metallic fragment or foreign body
* Hearing aid
* Other implant
* Subject injured by a metallic object or foreign body
* History of cancer within the past year
* Allergy or intolerance to any food or compound used
* Currently following a strict exercise program (minimum three times per week) in order to either lose weight, gain muscle or reach competition standards for a chosen sport
* Currently participating or having participated in a clinical trial during the past month
* Subjects not willing and/or not able to comply with scheduled visits and the requirements of the research protocol. Subject having a hierarchical link with the investigator or co-investigators.
* Subject who cannot be expected to comply with the research protocol.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ecole Polytechnique Fédérale de Lausanne
OTHER
Société des Produits Nestlé (SPN)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maurice Beaumont, MD
Role: PRINCIPAL_INVESTIGATOR
Société des Produits Nestlé (SPN)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Metabolic Unit, Clinical Development Unit, Nestec
Lausanne, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16.19.CLI
Identifier Type: -
Identifier Source: org_study_id